Recombinant
RabMAb

Recombinant Anti-FAT10 antibody [EPR4370] (HRP) (ab202921)

Overview

  • Product name
    Anti-FAT10 antibody [EPR4370] (HRP)
    See all FAT10 primary antibodies
  • Description
    Rabbit monoclonal [EPR4370] to FAT10 (HRP)
  • Host species
    Rabbit
  • Conjugation
    HRP
  • Tested applications
    Suitable for: WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse
  • Immunogen

    within Human FAT10 aa 100 to the C-terminus. The exact sequence is proprietary.
    Database link: O15205

  • Positive control
    • WB: HepG2, MOLT4 and K562 whole cell lysate.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab202921 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/5000. Detects a band of approximately 24 kDa (predicted molecular weight: 18 kDa).

Target

  • Function
    Ubiquitin-like protein modifier which can be covalently attached to target protein and subsequently leads to their degradation by the 26S proteasome, in a NUB1L-dependent manner. Probably functions as a survival factor. Conjugation ability activated by UBA6. Promotes the expression of the proteasome subunit beta type-9 (PSMB9/LMP2). Regulates TNF-alpha-induced and LPS-mediated activation of the central mediator of innate immunity NF-kappa-B by promoting TNF-alpha-mediated proteasomal degradation of ubiquitinated-I-kappa-B-alpha. Required for TNF-alpha-induced p65 nuclear translocation in renal tubular epithelial cells (RTECs). May be involved in dendritic cell (DC) maturation, the process by which immature dendritic cells differentiate into fully competent antigen-presenting cells that initiate T cell responses. Mediates mitotic non-disjunction and chromosome instability, in long-term in vitro culture and cancers, by abbreviating mitotic phase and impairing the kinetochore localization of MAD2L1 during the prometaphase stage of the cell cycle. May be involved in the formation of aggresomes when proteasome is saturated or impaired. Mediates apoptosis in a caspase-dependent manner, especially in renal epithelium and tubular cells during renal diseases such as polycystic kidney disease and Human immunodeficiency virus (HIV)-associated nephropathy (HIVAN).
  • Tissue specificity
    Constitutively expressed in mature dendritic cells and B cells. Mostly expressed in the reticuloendothelial system (e.g. thymus, spleen), the gastrointestinal system, kidney, lung and prostate gland.
  • Sequence similarities
    Contains 2 ubiquitin-like domains.
  • Post-translational
    modifications
    Can be acetylated.
  • Cellular localization
    Nucleus. Cytoplasm. Accumulates in aggresomes under proteasome inhibition conditions.
  • Information by UniProt
  • Database links
  • Alternative names
    • Diubiquitin antibody
    • FAT10 antibody
    • GABBR1 antibody
    • UBD 3 antibody
    • Ubd antibody
    • UBD_HUMAN antibody
    • Ubiquitin D antibody
    • Ubiquitin like protein FAT10 antibody
    • Ubiquitin-like protein FAT10 antibody
    see all

Images

  • All lanes : Anti-FAT10 antibody [EPR4370] (HRP) (ab202921) at 1/5000 dilution

    Lane 1 : HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate
    Lane 2 : MOLT4 (Human acute lymphoblastic leukemia cell line) Whole Cell Lysate
    Lane 3 : K562 (Human erythromyeloblastoid leukemia cell line) Whole Cell Lysate

    Lysates/proteins at 10 µg per lane.

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 18 kDa
    Observed band size: 24 kDa
    why is the actual band size different from the predicted?


    Exposure time: 20 seconds


    This blot was produced using a 4-12% Bis-tris gel under the MES buffer system. The gel was run at 200V for 35 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab202921 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.

References

ab202921 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

Application
ELISA
Sample
Human Recombinant protein (mature dendritic cells and B cells)
Specification
mature dendritic cells and B cells
Blocking step
BSA as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 0.25µg/mL · Temperature: 23°C
Type
Sandwich (Detection)

Abcam user community

Verified customer

Submitted Feb 25 2019

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
For licensing inquiries, please contact partnerships@abcam.com

Sign up